Results from a Phase II trial for cardiovascular disease with an epigenetic target therapy show promise.
Advertisement
The Nutshell
Daily News Roundup
Most Recent
A human trial of a hepatitis C treatment is shut down after one of the participants died.
Another person has died from the rodent-borne disease after visiting Yosemite National Park.
Researchers consider the recent reappearance of West Nile virus in Texas and the efforts to control it.
The market for drugs that target rare diseases is expected to rival big pharma blockbusters in the coming decades.
Proposals from researchers receiving more than $1 million a year in NIH funding will be carefully picked over to avoid overlap with ongoing research.
A polar bear in a German zoo dies after contracting a virus normally found in zebras.
A former manager at Genentech claims the company bypassed ethical and clinical guidelines in order to rush a promising drug through clinical trials.
Patent expirations of one HIV drugs will make the disease cheaper—but also more cumbersome—to treat.
The rise in the amount of federal money requested through research grants is due to a rise in the overall number of applicants.
Subjects
- cancer
- cell & molecular biology
- culture
- disease/medicine
- ecology
- evolution
- funding
- genetics & genomics
- NIH
- policy
Sub Categories
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
